Vanda Pharmaceuticals reports positive data from motion sickness trial

Vanda Pharmaceuticals has reported positive outcomes from its second Phase III clinical trial of tradipitant, aimed at treating motion sickness.

Dubbed Motion Serifos, the double-blind, randomised, multicentre, placebo-controlled trial involved 316 participants with a history of motion sickness.